Accordingly, whilst ASPs have historically been maintained, this influx of lower-cost solutions is forecast to impact the market significantly over the coming years.
3. Interest and growth is expected to be driven elsewhere
Breast imaging is beginning its transition into a multi-modality practice, incorporating ultrasound and MR technologies with increased frequency.
Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.
Several large-scale studies are currently taking place evaluating the impact of the implementation of risk-based programmes. These, which include the MyPeBs and WISDOM trials, are large scale in size, and differ from the current age-based screening model.
Implementation of these programmes is likely to see mammography play a principal, but less pronounced, role in screening as supplemental modalities begin to rise in popularity. This trend can be seen in its infancy in the US where the continued impact of breast density campaigns is expected to lead to a corresponding rise in supplemental ultrasound screening.
Mammography’s pitfalls have been well-publicised for some time, especially in dense breasts, and whilst DBT shows some promise in offering increased sensitivity compared to its 2D counterparts, research relating to this is much less widespread than that relating to the use of ultrasound.
Vendors are therefore considered more likely to begin to invest in supplemental modality systems once these programmes begin implementation, to the detriment of the mammography market.
Provider interest is therefore expected to be driven elsewhere, and the slowdown in mammography market growth is expected to herald the adoption of newer technologies in BI.
As DBT has become more widely distributed, the case for machine learning has strengthened. Countries such as Sweden have now begun trials examining the large-scale implementation of programs where machine learning is being used in conjunction with DBT, and as the forecast continues, growth in this segment is expected to be strong, particularly in the North American and Western European markets.
ABUS systems, previously side-lined by DBT technologies, are also now projected to gain more prominence as awareness of ultrasound imaging in dense breasts rises. Markets such as China and Japan, which also form significant parts of the mammography market, are forecast soon to increase their uptake of ABUS imaging systems. And whilst mammography will remain a mainstay in these countries, the potential use of a modality tailored for typically dense-breasted populations offers an attractive alternative for providers.